Egg Albumin-Based Protein Supplement Versus Renal-specific Supplement in Hemodialysis Patients

Randomized, Open Label, Controlled Clinical Trial of Egg Albumin-Based Protein Supplement Versus Renal Specific Oral Supplement in Hemodialysis Patients

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01981083

Enrollment

Registered

2013-11-11

Start date

2013-11-30

Completion date

Unknown

Last updated

2013-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis, Kidney Failure, Chronic, Protein-Energy Malnutrition

Keywords

Protein-Energy Malnutrition, Chronic Kidney Disease, Malnutrition-Inflammation Score, Subjective Global Assessment, Hemodialysis, Egg albumin

Brief summary

Malnutrition is seen frequently in hemodialysis units in most developing countries. Malnutrition increases morbidity and mortality in this population and its treatment improves patient survival and health status The purpose of this study is to compare two strategies to improve nutritional status in hemodialysis patients: renal-specific oral supplement (237 ml) versus egg albumin-based protein supplement (30 g) on a daily basis. This trial uses the Malnutrition Inflammation Score (MIS) and Subjective Global Assessment (SGA) in addition to most used biochemical markers to determine nutritional status.

Interventions

DIETARY_SUPPLEMENTEgg albumin-based protein supplement

DIETARY_SUPPLEMENTRenal-specific oral supplement

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Chronic Kidney Disease in Hemodialysis

Exclusion criteria

* Infection * Liver insufficiency * Cancer or neoplasia * Acquired immunodeficiency syndrome * Intestinal malabsorption syndrome

Design outcomes

Primary

Measure	Time frame
Change in Malnutrition-Inflammation Score	Bimonthly, up to six months
Change in Subjective Global Assessment	Bimonthly, up to six months

Countries

Mexico

Contacts

Primary ContactRafael Gonzalez-Toledo, MD

rtoledo29@yahoo.com.mx52(722)2760860

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026